A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
暂无分享,去创建一个
M. Campone | A. Manikhas | L. Dirix | J. O’Shaughnessy | S. Delaloge | Q. Khan | A. Chan | M. Ramos Vázquez | E. di Tomaso | C. Massacesi | P. Urban | R. Hegg | E. Tomaso | S. Goteti | M. R. Borrego | P. Krivorotko | M. Martín | M. Ruíz Borrego | M. Shtivelband | N. Batista López | J. Beck | N. López | M. Martín | A. Chan | M. Campone | M. R. Vazquez
[1] R. Laing,et al. 1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC) , 2015 .
[2] Andrew Menzies,et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.
[3] Michael G. Kharas,et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.
[4] M. Piccart,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] T. Miller,et al. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways , 2014, Pharmacogenomics and personalized medicine.
[6] J. Bendell,et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors , 2014, Investigational New Drugs.
[7] Frank Bretz,et al. Some practical considerations for phase III studies with biomarker evaluations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Yardley,et al. Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes , 2013, International journal of breast cancer.
[9] W. Gradishar,et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. , 2013, European journal of cancer.
[10] J. Machiels,et al. Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors , 2012 .
[11] B. Park,et al. Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy , 2012, Journal of Mammary Gland Biology and Neoplasia.
[12] J. Crown,et al. Emerging targeted therapies in triple-negative breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[14] W. Sellers,et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.
[15] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[16] Frank Bretz,et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.
[17] M. Hung,et al. Induction of Akt activity by chemotherapy confers acquired resistance. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.
[18] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[19] R. Carlson. NCCN breast cancer clinical practice guidelines in oncology: an update. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] G. Mills,et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.